Overview

Study of PF-04523655 (REDD14NP) In Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (Wet AMD)

Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to evaluate whether PF-04523655 is safe in the treatment of neovascular/wet AMD
Phase:
Phase 1
Details
Lead Sponsor:
Quark Pharmaceuticals
Collaborator:
Pfizer